ClinicalTrials.gov
public full text
Public Domain
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
The study is designed to show that everolimus initiation together with reduction and thereafter discontinuation of calcineurin inhibitor (CNI) will improve significantly renal function in de novo liver transplant recipients as compared to continuation of CNI-based treatment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation#272293
- Safety Use of ATeGe in Liver Transplant Recipients With Pre-transplant Renal Dysfunction#1058823
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients#881054
- An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens#887760
- Study Evaluating Sirolimus in the Treatment of Kidney Transplant#1009919
Record · ID 1363020
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive